Dimethyl fumarate
Dimethyl fumarate (Tecfidera), NRF2 pathway activator
Written by Aaron CuhaReviewed Sep 2026
Also known as: DMF, Tecfidera, Skilarence
An approved multiple sclerosis drug and the cleanest available NRF2 activator. It did not extend mouse lifespan, and the paper reports the dose delivered averaged only 35 percent of target, which the authors say may explain that.
Overview
NRF2 is the master transcriptional regulator of the antioxidant and detoxification response, and activating it is one of the most cited mechanisms in longevity supplementation. Sulforaphane, curcumin and a long list of plant compounds are all sold on this basis. Dimethyl fumarate is the only NRF2 activator that is an approved drug with a known dose, which makes it the best way to test whether activating that pathway extends life.
In the Interventions Testing Program's 2024 cohort it did not increase lifespan in either sex. But this is the one null in the batch that comes with a genuine asterisk, supplied by the authors themselves: the amount of dimethyl fumarate in the diet averaged 35 percent of the target dose, and they state this may explain the absence of a lifespan effect.
A null at roughly a third of the intended dose is a weaker result than a null at the intended dose, and reporting it without that caveat would be misleading.
Mechanism of action
An electrophile that modifies cysteine residues on KEAP1, the protein that normally tags NRF2 for degradation. Disabling KEAP1 lets NRF2 accumulate and enter the nucleus, where it drives transcription of antioxidant response element genes including glutathione synthesis enzymes, NAD(P)H quinone dehydrogenase 1 and haem oxygenase 1. It also depletes glutathione acutely and has immunomodulatory effects independent of NRF2, including lymphocyte reduction, which is relevant to its multiple sclerosis efficacy and its main risk.
Human evidence
A substantial approved-drug record in multiple sclerosis and psoriasis. No ageing endpoints in humans.
- Approved for relapsing multiple sclerosis on randomised trials showing reduced relapse rate and lesion activity.
- Used in Europe for psoriasis, where fumaric acid esters have a long history.
- Flushing and gastrointestinal effects are common early and usually settle.
- Lymphopenia is the important risk, because prolonged severe lymphopenia has been associated with progressive multifocal leukoencephalopathy, so lymphocyte counts are monitored.
- No human study has examined lifespan, healthspan or any ageing endpoint.
What this does not tell you: The human evidence is about an autoimmune disease of the central nervous system and does not transfer to healthy ageing. The mouse lifespan null is compromised by a delivered dose averaging 35 percent of target, so the NRF2-and-lifespan question is closer to untested than to answered.
Reading the research record
This page is the reason a null needs reading rather than counting. Taken at face value, the most rigorous lifespan programme in the field tested the best-characterised NRF2 activator and found nothing, which would be a serious problem for a very large number of supplements sold on NRF2 activation. Read properly, the delivered dose averaged 35 percent of target and the authors themselves offer that as the likely explanation.
So the honest position is that the NRF2 hypothesis has not yet had a fair lifespan test, and that anyone citing this cohort as evidence against NRF2 activation is overreading it in one direction while anyone ignoring the null is overreading it in the other.
The Interventions Testing Program is run by the National Institute on Aging at three independent sites, The Jackson Laboratory, the University of Michigan and the University of Texas Health Science Center at San Antonio. It uses UM-HET3 mice, a genetically heterogeneous four-way cross, so a result cannot be an artefact of one inbred strain. Compounds are fed in the diet, both sexes are tested, cohorts are large enough to detect roughly a 10 percent lifespan change, and results are analysed by log-rank for median survival and by the Wang-Allison test for maximum lifespan. Its nulls are published alongside its positives. That combination of features does not exist anywhere else in ageing research, which is why a null here means considerably more than a null from a single laboratory.
The evidence, charted
Fig. 1 · evidence composition
0of 1 citation (0%) is in people
Every citation cited here is Animal work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Every citation here was published in 2024.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2024
Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002, dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not
Interventions Testing Program. Dimethyl fumarate did not increase lifespan significantly in either sex at the dose and method of administration tested. The authors report that the amount in the diet averaged 35 percent of the target dose, which they state may explain the absence of lifespan effects. Note the disclosed conflicts in this paper: two authors run a company supplying the astaxanthin used, and others hold senolytic patents or company interests.
GeroScience
Frequently asked questions
Does activating NRF2 extend lifespan?
Untested rather than answered. The one attempt using a well-characterised NRF2 activator found no lifespan effect, and the delivered dose averaged 35 percent of target, which the authors say may explain it. That leaves the question open.
Should I take dimethyl fumarate for longevity?
No. It requires lymphocyte monitoring because prolonged severe lymphopenia has been linked to a serious brain infection, and there is no benefit signal for ageing to weigh against that. If NRF2 activation is your interest, the honest answer is that nobody has shown it extends life in a mammal.
Is this the same as taking sulforaphane or curcumin?
They share a proposed mechanism and differ in almost everything else that matters: potency, dose certainty, bioavailability and evidence base. Dimethyl fumarate is a prescription drug with a known dose, which is exactly why it was chosen for the lifespan test.